Alpha Cognition Inc
ACOG
株式のランク
#20419
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
株価
$8.13
最終同期: 2026-10-16
時価総額
$126.27M
変化（1日）
-3.79%
変化（1年）
61.63%
国
US
取引 Alpha Cognition Inc (ACOG)
カテゴリー
Healthcare
の時価総額 Alpha Cognition Inc(ACOG)
時価総額: $126.27M
October 2026時点で、Alpha Cognition Inc の時価総額は $126.27M です。これは、当社のデータによると、Alpha Cognition Inc が世界で20419th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Alpha Cognition Inc の時価総額の履歴（2021 から 2026 まで）
